Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bellaie, Texas Clinical Trials

A listing of Bellaie, Texas clinical trials actively recruiting patient volunteers.

RESULTS

Found (25) clinical trials

Surgical Idiopathic Intracranial Hypertension Treatment Trial

After signing the informed consent form, potential subjects will be assessed for eligibility, including eliciting medical and neurologic history, measurement of best-corrected visual acuity, visual field testing, ophthalmoscopy with optic disc edema grading, physical examination, and Optical Coherence Tomography (OCT). Questionnaires will be completed. Blood will be drawn for complete ...

Phase

2.12 miles

Learn More »

The Safety Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream 0.3% or ARQ-151 cream 0.15% or vehicle cream is applied once daily for 84 days to subjects with chronic plaque psoriasis involving between 2 and 20% body surface area.

Phase

2.74 miles

Learn More »

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

PRIMARY OBJECTIVES: I. Evaluate the safety and determine the maximum tolerated dose (MTD) of ADCT-602 in patients with relapsed or refractory B-cell (B)-acute lymphoblastic leukemia (ALL) in Phase 1. II. Determine the recommended dose of ADCT-602 for Phase 2. III. Evaluate the efficacy (complete response [CR] with incomplete marrow recovery ...

Phase

3.47 miles

Learn More »

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-1)

A multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial, which will randomize approximately 1140 subjects in a ratio of 1:1:1 to receive IVT injections of 0.5 mg conbercept, 1.0 mg conbercept, or 2.0 mg aflibercept. The trial includes a screening period of less than or equal to 14 days, followed ...

Phase

3.47 miles

Learn More »

Clinical Outcome Following Arthroscopic Knee Surgery

Purpose: There are no existing data available to guide clinicians in the appropriate rehabilitation progression of patients who have undergone knee arthroscopy. The investigator intends to fill this void by establishing normative recovery curves for patients undergoing knee arthroscopy. Research Design: Prospective Observational Design Procedures: Patients 10-70 years old will ...

Phase N/A

3.47 miles

Learn More »

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

To determine whether use of detemir compared to neutral protamine hagedorn (NPH) decreases rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2 Diabetes Mellitus (T2DM).

Phase

3.47 miles

Learn More »

Tinostamustine Conditioning and Autologous Stem Cell

Study Design (Methodology): This is a 2-part, international, multi-center, open-label study of salvage treatment with tinostamustine conditioning followed by ASCT in patients with relapsed/ refractory multiple myeloma (MM). (ASCT is defined as salvage if the patient had already received a prior ASCT and undergoes a second ASCT after evidence of ...

Phase

3.47 miles

Learn More »

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide subcutaneous (SC) injections in patients with short bowel syndrome (SBS).

Phase

3.47 miles

Learn More »

Monitoring Detoxifying and Rebalancing Metals During Front Line Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy

Study Groups: If you are found to be eligible to take part in this study, the study doctor will assign you to receive either Ca-EDTA alone or DMSA alone. This will depend on what the doctor thinks is in your best interest and which treatments are available. The study doctor ...

Phase

3.47 miles

Learn More »

Ulixertinib in Treating Patients With Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with BVD-523FB (ulixertinib) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in the MAPK pathway. SECONDARY OBJECTIVES: I. To ...

Phase

3.47 miles

Learn More »